BPC November 01 update

ImmunoGen IMGN and Intersect XENT shares rally on earnings; ​BeiGene BGNE shares up 37%

Price and Volume Movers

BeiGene, Ltd. (NASDAQ:BGNE) shares closed Friday up 37% to $189.56 following news released late-Thursday of a collaboration with Amgen (NASDAQ: AMGN) for the commercialization and development in China of Amgen's oncology drugs. Amgen will purchase a 20.5% stake in BeiGene for approximately $2.7b in cash.

ImmunoGen, Inc. (NASDAQ: IMGN) shares closed up 28% to $3.04 following the release of third-quarter earnings. Revenue was up to $13.3m compared with $10.9m in the same quarter last year and higher than analyst estimates.

Intersect ENT (NASDAQ:XENT) shares closed up 21% to $21.63 also on the back of third-quarter earnings. While its loss for the quarter was larger than expected, the company is maintaining its outlook for revenue for the full year 2019 to be approximately flat compared with 2018 revenue of $108.5m.

Rexahn Pharmaceuticals (NASDAQ: REXN) shares closed up 24% to $2.09. The price surge appears to be in reaction to an article published in the journal Molecular Cancer Therapeutics of a preclinical trial evaluate the efficacy of RX-5902 in models of triple-negative breast cancer (TNBC).

Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) shares closed up 30% to $1.07. The company announced Thursday that an abstract for a preclinical investigation from its natural killer cell chimeric antigen receptor (CAR-NK) program has been accepted for poster presentation at the SITC Meeting on November 8.

-

Major price movers (stocks priced > $1.00, volume > 50k):

Refer to the BioPharmCatalyst Biotech Stocks page for Top 10 Gainers/Losers/Unusual Volume

ADVANCERS:

Hoth Therapeutics, Inc. (HOTH): $4.74; +42%.

Tonix Pharmaceuticals Holding Corp. (TNXP): $3.61; +23%.

Acorda Therapeutics, Inc. (ACOR): $2.00; +21%.

IVERIC bio, Inc. (ISEE): $3.80; +16%.

Calithera Biosciences, Inc. (CALA): $3.33; +16%.

DECLINERS:

Neon Therapeutics, Inc. (NTGN): $1.92; -9%.

Oncolytics Biotech Inc. (ONCY): $1.15; -8%.

vTv Therapeutics Inc. (VTVT): $1.38; -7%.

Moderna, Inc. (MRNA): $15.66; -7%.

Tetraphase Pharmaceuticals, Inc. (TTPH): $3.29; -6%.

Pipeline updates below:

Pipeline Database Updates

Drug Stage Catalyst Market Cap

BCRX – BioCryst Pharmaceuticals Inc.
BCX9250
Fibrodysplasia ossificans progressiva (FOP)

Phase 1 Phase 1 initiation announced November 1, 2019. Data due 2H 2020.
$247.4 million

BHVN – Biohaven Pharmaceutical Holding Company Ltd.
TRORILUZOLE
Alzheimer’s disease

Phase 2 Phase 2/3 futility analysis due 4Q 2019.
$2.8 billion

BHVN – Biohaven Pharmaceutical Holding Company Ltd.
Rimegepant
Migraine - preventative

Phase 3 Phase 3 top-line data due 4Q 2019 or early-1Q 2020.
$2.8 billion

BHVN – Biohaven Pharmaceutical Holding Company Ltd.
Vazegepant
Acute treatment of migraine

Phase 2/3 Phase 2/3 top-line data due 4Q 2019.
$2.8 billion

CARA – Cara Therapeutics Inc.
KORSUVA (CR845/difelikefalin) injection - KALM-1
Chronic kidney disease (CKD) on hemodialysis (HD) with Moderate-to Severe Pruritus

Phase 3 Phase 3 data met primary endpoint - May 29, 2019.
$1.1 billion

CRTX – Cortexyme Inc.
COR388 - GAIN
Alzheimer’s disease

Phase 2/3 Phase 2/3 top-line data due 4Q 2021.
$673.4 million

IMGN – ImmunoGen Inc.
IMGN632
Acute Myeloid Leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN)

Phase 1 Phase 1 updated data due at ASH December 9, 2019, 3:00pm EST.
$490.1 million

NVO – Novo Nordisk A/S
Concizumab - Explorer 7
Hemophilia A

Phase 3 Phase 3 data due 1H 2021.
$127.6 billion

OVID – Ovid Therapeutics Inc.
OV101 - NEPTUNE
Adolescents with Angelman syndrome

Phase 3 Phase 3 data due mid-2020.
$107.1 million

PULM – Pulmatrix Inc.
PUR1800
Acute exacerbation of chronic obstructive pulmonary disease (AECOPD)

Phase 2a Phase 2a data due 2H 2020.
$16 million

YMAB – Y-mAbs Therapeutics Inc.
Omburtamab
CNS/Leptomeningeal Metastases from Neuroblastoma

BLA Filing BLA filing due 1Q 2020.
$1.1 billion